Prostate cancer screening among family physicians in Ontario: An update on attitudes and current practice

Jason Paul Akerman, Christopher B. Allard, Camilla Tajzler, Anil Kapoor

Abstract


Introduction: This study serves as an update of prostate cancer screening practices among family physicians in Ontario, Canada. Since this population was first surveyed in 2010, the Canadian Task Force on Preventive Health Care (CTFPHC) and the United States Preventive Services Task Force (USPSTF) released recommendations against prostate cancer screening.

Methods: An online survey was developed through input from urologists and family practitioners. It was distributed via email to all members of the Ontario Medical Association’s Section on General and Family practice (11 657 family physicians). A reminder email was sent at two weeks and the survey remained active for one month.

Results: A total of 1880 family physicians completed surveys (response rate 16.1%). Overall, 80.4% offered prostate cancer screening compared to 91.7% when surveyed in 2010. Physicians new to practice (two years or less) were the most likely to not offer screening (24.6%). A combination of digital rectal exam (DRE) and prostate-specific antigen (PSA) remained the most common form of screening (58.3%). Following the release of the CTFPHC recommendations, 45.6% of respondents said they now screen fewer patients. Participants were less familiar with national urological society guidelines compared to task force recommendations. The majority (72.6%) of respondents feel PSA screening leads to overdiagnosis and treatment. Those surveyed remained split with respect to PSA utility.

Conclusions: Data suggest a decline in screening practices since 2010, with newer graduates less likely to offer screening. CFTPHC and USPSTF recommendations had the greatest impact on clinical practice. Those surveyed were divided with respect to PSA utility. Some additional considerations to PSA screening in the primary care setting, including patient-driven factors, were not captured by our concise survey.


Full Text:

EPUB (DRAFT)

References


Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273:548-52.

Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157: 120-34.

Bell N, Gorber SC, Shane A, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014;186:1225-34.

Gibbons L, Waters C. Prostate cancer: testing, incidence, surgery and mortality. Health Rep 2003;14:9-20.

Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increasing through prostate-specific antigen-based screening. JAMA 1993;270:948-54.

Coldman AJ, Phillips N, Pickles TA. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003;168:31-5.

Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: interpreting trends in prostate cancer – part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999;91:1033-9.

Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.

Schröder FH, Hugosson J, Roobol M, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.

Hayes JH, Barry JM. Screening for prostate cancer with the prostate-specific antigen test: A review of current evidence. JAMA 2014;311:1143-9.

Wilt TJ, Scardino PT, Carlsson SV, et al. Prostate-specific antigen screening in prostate cancer: Perspectives on the evidence. J Natl Cancer Inst 2014;106:dju010.

Allard CB, Dason S, Lusis J, et al. Prostate cancer screening: Attitudes and practices of family physicians in Ontario. Can Urol Assoc J 2012;6:188-93.

Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. American Urological Association. https://www.auanet.org/education/guidelines/prostate-cancer-detection.cfm. Accessed March 1, 2016.

Klotz L, Breau R, Chin J, et al. CUA response to CTFPHC PSA screening recommendations. Canadian Urological Association. https://www.cua.org/.../psa/cua_response_to_ctfphc_psa_oct__2014.pdf. Accessed March 1,2016.

Bhindi B, Mamdani M, Kulkarni GS, et al. Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on prostate biopsy and cancer detection rates. J Urol 2015;193:1519-24.

Zeliadt SB, Hoffman RM, Etzioni R, et al. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 2011;103:520-3.

Cohn JA, Wang CE, Lakeman JC, et al. Primary care physician screening practices before and after the final U.S. preventive services task force recommendation. Urol Oncol 2014;32:41.

Volk RJ, Linder SK, Kallen MA, et al. Primary care physicians’ use of an informed decision-making process for prostate cancer screening. Ann Fam Med 2013;11:67-74.

Tasian GE, Cooperberg MR, Potter MB, et al. PSA screening: determinants of primary care physician practice patterns. Prostate Cancer Prostatic Dis 2012;15:189-94.

Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054-61.

Perez TY, Danzig MR, Ghandour RA, et al. Impact of the 2012 United States Preventive Services Task Force Statement on Prostate-specific Antigen Screening: Analysis of urologic and primary care practices. Urology 2015;85:85-91.

Crawford ED, Grubb R 3rd, Black A, et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011;29: 355–61.

Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–90.

Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–32.

US Preventive Services Task Force (USPSTF) Screening for Prostate Cancer website. [updated 2017 April]. http://www.screeningforprostatecancer.org. Accessed April 14, 2017.




DOI: http://dx.doi.org/10.5489/cuaj.4631
 |  Add comment